<DOC>
	<DOCNO>NCT01674556</DOCNO>
	<brief_summary>The investigator primary aim increase chemotherapeutic drug uptake inoperable tumours The specific sub-objectives study : - To quantify tumour size relate patient survival time , dependent treatment method . - To evaluate compare toxic effect safety gemcitabine combination US contrast agent sonication gemcitabine alone . - Develop validate new ultrasound perfusion algorithm base burst- replenishment diagnosis monitoring therapy . - To quantify gemcitabine main metabolite plasma circulate mononuclear cell , pancreatic sonication , quantify concentration intracellular endogenous nucleotide circulate mononuclear cell time point . - To assess plasma tissue concentration gemcitabine , main metabolite endogenous nucleotide patient surgical resection perform standard clinical indication .</brief_summary>
	<brief_title>Ultrasound-assisted Treatment Inoperable Pancreatic Cancer</brief_title>
	<detailed_description>The primary outcome monitor toxicity effect combination therapy .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<criteria>Patients inoperable pancreatic cancer ( ICD10 C25.03 ) Department Surgical Gastroenterology Haukeland University Hospital , volunteer participate Patient participate investigational study within 30 day prior study entry ( , longer , within five halflives last dose investigational drug ) . Patient severe chronic obstructive pulmonary disease severe chronic asthma . Patient history cardiovascular ischemia , acute myocardial infarction unstable angina within 3 month prior study entry . Patient history psychiatric disorder cognitive impairment would interfere participation study . Patient known history Hepatitis B , Hepatitis C HIV infection . Patient require dialysis severely impaired renal function , define serum creatinine &gt; 180 mmol/L Screening Visit . Patient severe impairment liver function , define serum albumin level ≤ 25 g/L and/or Protrombin Time INR &gt; 2.3 ( APTT &gt; 6 second upper limit normal ) Screening Visit . Patient pregnant breastfeeding . Patient allergic intolerant gemcitabine Patient allergic intolerant SonoVue® BRACCO ultrasound contrast agent Any reason , opinion investigator , patient participate .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>pancreatic</keyword>
	<keyword>cancer</keyword>
	<keyword>adenocarcinoma</keyword>
	<keyword>Ultrasound</keyword>
	<keyword>CEUS</keyword>
</DOC>